Bill Huizenga Consistently Voted To Raise Costs And Make Life Harder For Michigan Families, All While Saying Costs Were Coming Down
Huizenga Repeatedly Voted Against Lowering The Cost Of Prescription Drugs |
|---|
Huizenga Wanted To Reverse The Inflation Reduction Act, Which Established A $35 Per Month Cap On Insulin For Seniors On Medicare And Allowed Medicare To Negotiate The Cost Of Prescription Drugs
August 2022: Huizenga Voted Against The Inflation Reduction Act
August 2022: Huizenga Voted Against The Inflation Reduction Act. In August 2022, Huizenga voted against: “Yarmuth, D-Ky., motion to concur in the Senate amendment to the bill comprising a package of climate, tax and health care provisions. Among drug pricing provisions, the bill would require the Health and Human Services Department to negotiate a ‘maximum fair price’ with drug manufacturers for certain Medicare-eligible, brand-name drugs that do not have generic competition; cap cost-sharing for insulin products covered under Medicare at $35 a month; and require single-source drug manufacturers to provide rebates to HHS for the price of drugs under Medicare Parts B and D for which price increases outpace inflation. For Medicare Part D, it would cap the annual out-of-pocket limit at $2,000. It would extend through 2025 tax subsidies toward Affordable Care Act marketplace insurance premiums for individuals under a certain income level. The bill would provide for approximately $270 billion in new or expanded tax credits to incentivize actions by businesses and individuals to mitigate climate change, including production credits for electricity produced by renewable and nuclear facilities; investment tax credits for certain renewable energy equipment and facilities; and credits for advanced energy manufacturing projects, including in areas where a coal mine or power plant has closed. To incentivize emission reduction and clean fuel production, it would create or extend tax credits for carbon oxide sequestration facilities; biodiesel, renewable diesel and alternative fuels; and clean hydrogen facilities. For most of its corporate tax credits, it would add prevailing wage and apprenticeship requirements and establish bonus credits for using domestic materials in facility construction. It would also expand individual tax credits for residential energy efficiency improvements and renewable energy expenses; increase credits for new energy efficient homes; and create credits for the purchase of used electric vehicles by individuals under a certain income level. It would reinstate the Superfund tax on crude oil at a rate of 16.4 cents per barrel. Among other tax provisions, the bill would establish a 15 percent alternative minimum tax for corporations with a book income of at least $1 million annually and institute a 1 percent excise tax on corporate stock buybacks. It would authorize $79.3 billion for IRS operations, including enforcement activities and systems modernization. The bill would provide funding for various activities to reduce greenhouse gas emissions, promote energy-efficient technologies and mitigate the impacts of climate change, including $27 billion for grants to state, local and nonprofit entities for greenhouse gas emission reduction activities; $9.7 billion for zero-emission or carbon capture rural electric systems; $5 billion for loan guarantees to replace or reduce emissions of energy infrastructure; $3 billion for zero-emission vehicles for the Postal Service; and $1.6 billion for methane emissions reduction and mitigation. It would provide $9 billion for residential energy efficiency improvement rebates; $3 billion for new EPA environmental and climate justice block grants for community-led activities to address pollution, emission reduction, climate resiliency and public engagement; and $3 billion for Federal Highway Administration grants for projects that address surface transportation facilities that disconnect or negatively impact communities. It would provide $4 billion for drought mitigation in Western states; $2.15 billion for hazardous fuel reduction and restoration projects; and $1 billion to improve energy and water efficiency or climate resilience of affordable housing. It would require the Interior Department to accept bids for certain canceled oil and gas leases on the outer continental shelf. It would authorize wind lease sales adjacent to U.S. territories but prohibit new wind or solar development rights on federal lands for 10 years unless the department completes certain oil or gas lease sales.” The bill passed by a vote of 220-207. [H.R. 5376, Vote #420, 8/12/22; CQ, 8/12/22]
July 2025: Huizenga Said “We’ve Got To Reverse” The Inflation Reduction Act
Huizenga In July 2025: “We’ve Got To Reverse” The Inflation Reduction Act. “Congressman Bill Huizenga is expecting the U.S. House to get to work on Fiscal Year 2026 appropriations bills when it returns to Washington next week. While there’s been much talk about spending cuts included in the Big, Beautiful Bill, Huizenga says there are more coming. He tells us spending has been out of control on multiple fronts since COVID. ‘Because we had seen such a massive expansion in spending, for that money getting sent to states and locals and all those things, the so-called Inflation Reduction Act, which really did not do anything other than pick inflation up, we’ve got to reverse that, and a significant part of that is going to be our spending choices,’ Huizenga said.” [WSJM, 7/11/25]
The Inflation Reduction Act Capped The Cost Of Insulin And Out Of Pocket Costs For Medicare Recipients While Allowing The Federal Government To Lower The Cost Of Prescription Drugs For People On Medicare
KFF: The Inflation Reduction Act Would Lower The Cost Of Insulin To $35 A Month For People With Medicare. “The Inflation Reduction Act of 2022, signed into law by President Biden on August 16, 2022, includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government […] Limit monthly cost sharing for insulin to $35 for people with Medicare, beginning in 2023.” [KFF, 1/24/23]
NBC: The Inflation Reduction Act Allowed The Federal Government To Negotiate The Cost Of Prescription Drugs Starting In 2026. “The Inflation Reduction Act allows the federal government to negotiate prices for some of the drugs that Medicare spends the most money on, a long sought-after goal by Democrats and some Republicans. Previously, the U.S. government was explicitly prohibited from engaging in price negotiations with drugmakers on behalf of the Medicare population. The new law essentially establishes a process whereby the Health and Human Services secretary proposes the government’s offer price for certain drugs, said Tricia Neuman, senior vice president with the Kaiser Family Foundation. Starting in 2026, Medicare will begin negotiating the price of 10 drugs, followed by an additional 15 drugs in 2027, and eventually an additional 20 drugs in 2029 and beyond. The negotiation process applies to drugs covered under Medicare Part D that lack a generic or comparable alternative, though drugs under Medicare Part B will eventually be included.” [NBC News, 8/16/22]
- The Provision Would Lower The Cost Of 45 Different Drugs, Including Cancer Medications And Blood Thinners. “The Inflation Reduction Act, signed into law by President Joe Biden, is set to lower the cost of prescription drugs — including cancer medications, blood thinners and insulin — for millions of Americans, experts say. […] Starting in 2026, Medicare will begin negotiating the price of 10 drugs, followed by an additional 15 drugs in 2027, and eventually an additional 20 drugs in 2029 and beyond. The negotiation process applies to drugs covered under Medicare Part D that lack a generic or comparable alternative, though drugs under Medicare Part B will eventually be included.” [NBC News, 8/16/22]
NBC: The Inflation Reduction Act Lowered The Out Of Pocket Cap For Medicare Recipients By $5,000 To $2,000 A Year. “The law includes a $2000 out-of-pocket spending cap on prescription drugs for Medicare beneficiaries. It takes effect in 2025. Previously, people on Medicare had to spend about $7,000 out of pocket on their prescriptions before qualifying for ‘catastrophic coverage,’ according to Medicare's website. Under catastrophic coverage, patients are only charged either a copayment — which is a set amount, usually $10 or $20 per prescription — or a coinsurance percentage, which is set at 5% of the cost of the drug. Under the new law, in 2024, that 5% coinsurance will be reduced to zero, eliminating it.” [NBC News, 8/16/22]
NBC: The Inflation Reduction Act Reduced A 5% Coinsurance For Medicare Recipients “To Zero, Eliminating It.” “The law includes a $2000 out-of-pocket spending cap on prescription drugs for Medicare beneficiaries. It takes effect in 2025. Previously, people on Medicare had to spend about $7,000 out of pocket on their prescriptions before qualifying for ‘catastrophic coverage,’ according to Medicare's website. Under catastrophic coverage, patients are only charged either a copayment — which is a set amount, usually $10 or $20 per prescription — or a coinsurance percentage, which is set at 5% of the cost of the drug. Under the new law, in 2024, that 5% coinsurance will be reduced to zero, eliminating it.” [NBC News, 8/16/22]
March 2022: Huizenga Voted Against The Affordable Insulin Now Act, Which Would Cap The Price Of Insulin At $35 A Month March 2022: Huizenga Voted Against The Affordable Insulin Now Act
March 2022: Huizenga Voted Against The Affordable Insulin Now Act To Cap The Price Of Insulin At $35 A Month. In March 2022, Huizenga voted against: “Passage of the bill, as amended, that would require private health insurance and Medicare to cover certain insulin products and limit cost-sharing requirements for such products for plans beginning in 2023. Specifically, it would require private insurance plans to cover at least one of each dosage form of each type of insulin, such as short-acting, long-acting and premixed insulin; prohibit the plans from applying a deductible for the insulin products; and cap cost-sharing for the insulin products at the lesser of $35 or 25 percent of the plan's negotiated price for the product per 30-day supply. For Medicare plans, it would similarly prohibit the application of a deductible for covered insulin products and cap copayments at $35 per 30-day supply. The bill would also increase funding available for the Medicare Improvement Fund from $5 million to approximately $9 billion. As an offset, it would delay for an additional year, through Jan. 1, 2027, implementation of a November 2020 rule ending a safe harbor provision that protects pharmacy benefit managers from federal anti-kickback laws for prescription drug rebates provided to health insurers under Medicare Part D.” Passed by a vote of 232-193. [H.R. 6833, Vote #102, 3/31/22; CQ, 3/31/22]
The Affordable Insulin Now Act Capped The Price Of Insulin At $35 Or 25% Of An Insurance Plan’s Negotiated Price, Whichever Was Lower
The Affordable Insulin Now Act Capped The Price Of Insulin At $35 A Month Or 25% Of An Insurance Plan’s Negotiated Price, Whichever Was Lower. “The House of Representatives voted Thursday to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare. The vote was 232-193, with 12 Republican members joining their Democratic colleagues to pass the measure. The Affordable Insulin Now Act would cap insulin prices at either $35 a month or 25% of an insurance plan's negotiated price — whichever is lower. The legislation aims to take effect in 2023 but its fate in the Senate remains unclear.” [NPR, 3/31/22]
December 2019: Huizenga Voted Against Allowing The Federal Government To Negotiate Drug Prices Directly For Medicare Recipients And Others Purchasing The Same Drug
December 2019: Huizenga Voted Against the Elijah E. Cummings Lower Drug Costs Now Act
December 2019: Huizenga Voted Against the Elijah E. Cummings Lower Drug Costs Now Act, Which Would Allow The Federal Government To Negotiate Lower Drug Prices. In December 2019, Huizenga voted against: “Passage of the bill, as amended, that would allow the Health and Human Services Department to negotiate prices for certain drugs under Medicare programs and would make a number of modifications to Medicare programs related to drug costs and plan benefits. Specifically, the bill would establish a fair price negotiation program in which HHS would enter into agreements with drug manufacturers negotiate maximum fair prices for certain drugs.” The motion passed by a vote of 230-192. [HR 3, Vote #682, 12/12/19; CQ, 12/12/19]
The Lower Drug Costs Now Act Would Have Capped Seniors’ Out-Of-Pocket Costs For Prescription Drugs At $2,000 Per Year
Washington Post: The Lower Drug Costs Now Act Would Have Capped Seniors’ Out-Of-Pocket Costs For Prescription Drugs At $2,000 Per Year. “House Speaker Nancy Pelosi unveiled her long-awaited drug pricing measure on Thursday, an ambitious bill that would allow the federal government to negotiate the prices of up to 250 brand-name drugs in Medicare. […] It would also cap seniors’ out-of-pocket prescription drug costs at $2,000 a year. And it would require drug companies that have raised their prices above the inflation rate since 2016 to either lower their prices or rebate the portion back to the U.S. Treasury.” [Washington Post, 9/19/19]
The Lower Drug Costs Now Act Was A “Major Shift” In Drug Pricing, Allowing The Federal Government To Negotiate Drug Prices And Reduce Costs By 55 Percent
Vox: The Bill Was A “Major Shift” In Drug Pricing, Allowing The Federal Government To Negotiate Drug Prices Directly For Medicare Recipients And Others Purchasing The Same Drug. “House Democrats have officially introduced their big prescription drug pricing plan, but it’s unclear just how much traction it can get in a divided Congress. Speaker Nancy Pelosi unveiled the proposal on Thursday in a bid to address one of Democrats’ chief 2018 campaign promises: Last fall, lawmakers across the country pledged to bring down the increasingly exorbitant prices voters face for different medications. According to a summary shared by Pelosi’s office, the Democrats’ proposal would mark a major shift in the way prescription drug prices are set in the US by empowering the federal government to directly negotiate drug prices for Medicare recipients as well as others purchasing the drug.” [Vox, 9/19/19]
Congressional Budget Office: H.R. 3’s Negotiation Provision Would Reduced Drug Prices By 55 Percent. “CBO then estimated net spending for drugs with the international prices selected for negotiation under title I [of H.R. 3]. CBO estimates that reducing prices to 114 percent of the AIM price, on average, would reduce—by nearly 55 percent—the prices for the first group of drugs subject to negotiation.” [Congressional Budget Office, 10/11/19]
2025: Huizenga Voted For The Big Beautiful Bill, Which Included An $8.8 Billion Handout For Pharma Companies Thanks To New Restrictions On Medicare Prescription Drug Price Negotiations
2025: Huizenga Voted To Give Pharmaceutical Companies An $8.8 Billion Handout By Preventing Lower Costs For “Some Of The Most Profitable Drugs On The Market”
July 3, 2025: Huizenga Voted For The Big Beautiful Bill. On July 3, 2025, Huizenga voted for: “Motion to concur in the Senate amendment to the bill that would permanently extend nearly $4 trillion in expiring individual and business tax cuts, create several new tax breaks and fund border and immigration enforcement and air traffic control upgrades. It would cut Medicaid and other safety net programs to partly offset the cost. Among other provisions, it would raise the statutory debt ceiling by $5 trillion and appropriate more than $448 billion in mandatory funding for Trump administration priorities and other needs, including $153 billion for defense, $89 billion for immigration enforcement, and $89.5 billion for border control and security. It also would increase the state and local tax deduction cap to $40,000 annually for five years for households making up to $500,000 a year until 2030, when it would permanently revert to $10,000.” Motion agreed to 218-214. [H.R.1, Vote #190, 7/3/25; CQ, 7/3/25]
- Press Release: “New CBO Report: Trump’s Big Ugly Bill Includes $8.8 Billion Handout for Pharmaceutical Companies.” [Congressman Frank Pallone Jr, Press Release, 10/20/25]
- Protect Our Care: The Big Beautiful Bill Put New Restrictions On “When And What Prescription Drugs Medicare Can Negotiate.” “Today, the nonpartisan Congressional Budget Office (CBO) revealed that Medicare will be missing out on $8.8 billion in savings over 10 years due to prescription drug pricing provisions in Donald Trump and Republicans’ tax bill. In the GOP bill, big drug companies scored one of their biggest victories in years, putting new restrictions on when and what prescription drugs Medicare can negotiate. Many of the medications that would be exempted under the new loophole are some of the most profitable drugs on the market and treat conditions such as cancer and hypertension. Seniors who rely on these life-saving medications will now have to wait longer for relief or may not receive any at all.” [Protect Our Care, Press Release, 10/20/25]
- The Loophole Exempted “Some Of The Most Profitable Drugs On The Market” From Medicare Price Negotiations. “Today, the nonpartisan Congressional Budget Office (CBO) revealed that Medicare will be missing out on $8.8 billion in savings over 10 years due to prescription drug pricing provisions in Donald Trump and Republicans’ tax bill. In the GOP bill, big drug companies scored one of their biggest victories in years, putting new restrictions on when and what prescription drugs Medicare can negotiate. Many of the medications that would be exempted under the new loophole are some of the most profitable drugs on the market and treat conditions such as cancer and hypertension. Seniors who rely on these life-saving medications will now have to wait longer for relief or may not receive any at all.” [Protect Our Care, Press Release, 10/20/25]
2009-2024: Huizenga Accepted Nearly $83,000 From The Pharmaceuticals/Health Products Industry
2009-2024: Huizenga Accepted $82,737 From The “Pharmaceuticals/Health Products” Industry. [OpenSecrets accessed 3/31/26]
Image: see original report, p. 44
2025-2026: Huizenga Repeatedly Voted To Increase 29,000 Of His Constituents’ Health Care Premiums And Raise Their Taxes |
|---|
2025-2026: Huizenga Repeatedly Criticized And Voted Against Extending The ACA Premium Tax Credits
2025-2026: Huizenga Voted Three Times Against Extending The ACA Premium Tax Credits
May 22, 2025: Huizenga Voted For Initial Passage Of The Big Beautiful Bill. On May 22, 2025, Representative Bill Huizenga voted for: “Passage of the bill that would provide for approximately $3.8 trillion in net tax cuts and $321 billion in military, border enforcement and judiciary spending, offset by $1.5 trillion in spending reductions, as instructed in the fiscal 2025 budget resolution (H Con Res 14). It would raise the statutory debt limit by $4 trillion and provide for increased spending on defense and border security, spending cuts on social safety net programs, such as Medicaid and the Supplemental Nutrition Assistance Program. It also includes a mix of tax breaks for businesses and individuals; tax increases on universities and foundations; and a phase-down of clean energy tax credits. It would reduce spending on Medicaid by $625 billion over a 10-year period and modify eligibility and cost provisions for enrollees and health providers and impose work, volunteer and education requirements on adults ages 19 to 64 who are covered by the program. It would appropriate “such sums as necessary” for reducing cost-sharing payments for low-income individuals who’ve purchased “silver” plans on the 2010 health care law’s exchanges. But payments to plans that cover abortions would be mostly barred. It would extend and make permanent individual tax brackets and rates included in the 2017 tax overhaul law (PL 115-97) and provide for the adjustment of the lower bounds of each tier based on inflation. It would reduce federal spending on the Supplemental Nutrition Assistance Program by requiring states to shoulder more of the cost, expand work requirements for SNAP, extend programs authorized under the 2018 farm bill, and prohibit the U.S. Department of Agriculture from increasing the cost of the Thrifty Food Program. As amended, it would cap state and local tax deductions at $40,000 for households with incomes below $500,000 and prohibit Medicaid funding for gender transition therapies or procedures for minors and adults, among other provisions.” The bill passed by a vote of 215-214. [H.R. 1, Vote #145, 5/22/25; CQ, 5/22/25]
July 3, 2025: Huizenga Voted For The Final Passage Of The Big Beautiful Bill. On July 3, 2025, Representative Bill Huizenga voted for: “Motion to concur in the Senate amendment to the bill that would permanently extend nearly $4 trillion in expiring individual and business tax cuts, create several new tax breaks and fund border and immigration enforcement and air traffic control upgrades. It would cut Medicaid and other safety net programs to partly offset the cost. Among other provisions, it would raise the statutory debt ceiling by $5 trillion and appropriate more than $448 billion in mandatory funding for Trump administration priorities and other needs, including $153 billion for defense, $89 billion for immigration enforcement, and $89.5 billion for border control and security. It also would increase the state and local tax deduction cap to $40,000 annually for five years for households making up to $500,000 a year until 2030, when it would permanently revert to $10,000.” Motion agreed to 218-214. [H.R.1, Vote #190, 7/3/25; CQ, 7/3/25]
- CNBC: The Big Beautiful Bill Did Not Extend The Affordable Care Acts “Enhanced Premium Tax Credits,” A Move That Would Cause A “Sharp Premium Increase.” “Republicans gave a roughly $4 trillion tax cut to Americans in the so-called ‘big beautiful bill’ that President Donald Trump signed into law July 4, extending several tax provisions scheduled to expire in 2026. However, there was a notable omission, according to health policy experts: an extension of a tax break that lowered health insurance premiums for millions of people. The enhanced premium tax credits, in place since 2021, have lowered the cost of health insurance premiums for those who buy coverage through the Affordable Care Act marketplace. Enrollees can use these to lower their premium costs upfront or claim the credits at tax time, but the credits are scheduled to expire after 2025. More than 22 million people — about 92% of ACA enrollees — received a federal subsidy this year that reduced their insurance premiums, according to KFF, a nonpartisan health policy research group. Those recipients would see a ‘sharp premium increase’ on Jan. 1, Cynthia Cox, the group’s ACA program director, said during a webinar Wednesday.” [CNBC, 7/11/25]
January 2026: Huizenga Voted Against A Discharge Petition That Would Have Extended The ACA Premium Tax Credits For Three Years. On January 8, 2026, Bill Huizenga voted against: “Passage of the bill, as amended, that would extend for three years, through the end of calendar year 2028, the enhanced tax credits to subsidize premiums for health insurance purchased on the Affordable Health Care Act health insurance markets. It would allow taxpayers whose household income exceeds 400 percent of the federal poverty line to receive tax credits for three more years. The measure would retroactively take effect Jan. 1, 2026.” The bill passed by a vote of 230-196. [H.R. 1834, Vote #11, 1/8/26; CQ, 1/8/26]
Huizenga Criticized The ACA Premium Tax Credits And Said Extending Them Would Be “Foolish”
January 2026: Huizenga Said A Three Year Extension Of The ACA Premium Tax Credits Was “Foolish.” “All seven of Michigan's Republicans in the House voted no, while the six Democrats voted yes. ‘Here's the thing: We have not rooted out the waste, fraud and abuse, which we are seeing in spades ― where you've got millions of people that have never made a claim and don't even know that they have been signed up for this,’ said U.S. Rep. Bill Huizenga, a Holland Republican. ‘This rush to just throw money at a problem without fixing the root cause of the problem is just foolish, in my mind.’” [Detroit News, 1/8/26]
November 2025: Huizenga Criticized A Proposal To Extend The ACA Premium Tax Credits, Calling It “Throwing More Money At A Broken System.” KEVIN DIETZ: “We talked to Congressman Tim Walberg yesterday and he said they're not going to pass Obamacare. Obamacare is a disaster. He said the Republicans want to talk about real reform. But will Democrats come to the table and talk about real reform?” HUIZENGA: “Well, we'll find out. We'll find out whether this is really about just throwing more money at a broken a broken system. And, oh, by the way, we're, all we're doing is really floating these massive, massive insurance companies. I mean, the money's not coming to the folks that need that help and need that that relief, it's going to these companies. And we haven't gotten at the root problem, which is Obamacare, the quote unquote, Affordable Care Act was that was not affordable and it doesn't work. It actually doesn't deliver the care that everybody was claiming it was going to back when it originally passed in 2008-9.” [WJR, All Talk, 05:14, 11/13/25] (AUDIO)
November 2025: Huizenga Bashed ACA Subsidies As “An Expensive Way” Of Making Life “More Affordable” For People. HUIZENGA: “Well, Liz, it’s good to be with you too. And I think you make an excellent, excellent point here which is, how do we make sure life is more affordable in general rather than just throwing a stimulus check, or subsidy for healthcare, or some of these other things out there. That’s an expensive way of doing that versus making sure that we have a reasonable taxation level.” [Fox Business, Mornings with Maria, 03:45, 11/17/25] (VIDEO)
December 2025: Huizenga Dismissed People On The ACA Exchange As Being Just Seven Percent Of The Population. HUIZENGA: “Well, and the question is regarding these COVID era enhanced subsidies that the Democrats put in place without any Republican input, knowing that they would be expiring this year and they had no plan, they didn't know what they were going to do other than declaring at the time this is a temporary payment. Oh, by the way, not to the to the patient, but to the insurance company. And now Chuck Schumer is out there trying to want to have people like me fix his problem. And, you know, to me, we've got to get to the root cause of why insurance and why health care specifically is less affordable for all Americans, not just the 7% of the people that access it through the Obamacare exchange.” [Steve Gruber Show, 07:00, 12/18/25] (VIDEO)
Huizenga’s Votes Against Extending The ACA Premium Tax Credits Would Both Raise Costs And Cause Thousands Of His Constituents To Lose Their Access To Care
KFF: 29,000 Michiganders In The 4th Congressional District Would See Their Premiums Increase Because Of The ACA Premium Tax Credits Not Being Extended. [KFF, 2/3/25]
10,500 Michiganders In The 4th Congressional District Would Lose Their ACA Coverage Because Of The Big Beautiful Bill Failing To Extend The ACA Premium Tax Credits. [Joint Economic Committee Minority, September 2025]
Institute On Taxation And Economic Policy: The Expiration Of The ACA Premium Tax Credits Would Increased The Average Michiganders’ Taxes In 2026
HEADLINE: “State-by-State Estimates of the First Year of Trump’s Tax Policies: All But the Richest Americans Face Higher Taxes.” [Institute On Taxation and Economy Policy, 2/23/26]
2026: The Average Michiganders’ Taxes Increased By 0.1 Percent Because Of The Expiration Of The ACA Premium Tax Credits. [Institute On Taxation and Economy Policy, Table, 2/23/26]
- 2026: Michiganders Earning $81,400 Or Less A Year Would See Their Taxes Increase Between 0.2-0.3 Percent Because Of The Expiration Of The ACA Premium Tax Credits. [Institute On Taxation and Economy Policy, Table, 2/23/26]
Image: see original report, p. 46
[Institute On Taxation and Economy Policy, Table, 2/23/26]
2 pages in this section